Novartis stock edges higher as oncology focus and new launches support growth

Novartis stock reflects the Swiss pharma group’s push in oncology and immunology, with recent results showing higher core earnings and a growing contribution from key drugs including Cosentyx and Kisqali.

Novartis stock, tied to the Swiss healthcare group Novartis AG (ISIN CH0012005267), stands on a multiyear transformation story driven by oncology and immunology therapies. The company is one of the largest global pharmaceutical players by revenue and market capitalization, with a diversified portfolio spanning innovative prescription medicines and generics. Over recent reporting periods Novartis has emphasized margin expansion, higher core earnings, and targeted investments into late stage assets, signaling a continued focus on profitable growth rather than volume alone.

Novartis is listed on the SIX Swiss Exchange in Zurich and also trades via American Depositary Receipts on the New York Stock Exchange, giving the group a broad investor base in Europe and North America. The company’s reporting currency is the Swiss franc, and its headline metrics typically include net sales, core operating income, and core earnings per share as key indicators of underlying performance. For equity investors, these numbers form the backbone of valuation discussions alongside the expected trajectory of blockbuster drugs and upcoming launches in oncology and immunology.

Revenue trends and earnings comparison

In a recent full year reporting cycle, Novartis generated group net sales of roughly CHF 50 billion, underscoring its status among the top tier of global pharmaceutical companies. This revenue base is spread across several therapy areas, with oncology and immunology representing important growth pillars. The company has communicated that its strategic focus is on high value medicines and discontinuation of lower margin, non core assets, which aligns earnings quality with long term portfolio positioning.

Core operating income, a key profitability metric that adjusts for restructuring and other non recurring items, has tracked above CHF 15 billion in the latest full year period. This level of core operating income supports healthy free cash flow generation and the capacity to fund research and development, bolt on acquisitions, and shareholder returns. Compared with earlier periods, Novartis has highlighted that core margin improvements reflect a mix shift toward higher value therapies and disciplined cost management.

Core earnings per share in the most recent full year results were in a high single digit Swiss franc range, translating the company’s operating performance into per share profitability. Investors commonly compare this core EPS against the prior year figure to gauge progress. For example, a comparison against an earlier reporting cycle shows that core EPS has increased, illustrating that Novartis has translated topline growth and margin expansion into genuine per share earnings improvement rather than relying solely on financial engineering. This quantified comparison between periods underpins much of the discussion around Novartis valuation multiples and future earnings power.

Oncology and immunology contribution

Novartis’ oncology franchise remains central to its growth strategy, with breast cancer therapy Kisqali and other targeted treatments contributing meaningfully to the topline. In recent periods the company has reported double digit percentage growth in oncology net sales, signaling strong market uptake and increasing penetration of key assets. This compares favorably with more modest growth rates in certain mature therapeutic areas, reinforcing the company’s focus on specialty and high value segments.

Immunology and dermatology are another prominent pillar, where Cosentyx has built a large revenue base across indications such as psoriasis and psoriatic arthritis. Over the past few years Novartis has shown that Cosentyx can deliver robust net sales growth, with revenue stepping up from mid single digit billions of Swiss francs toward higher levels. The year on year comparison across successive reporting cycles reveals that Cosentyx has consistently expanded its sales, helping to support group net sales expansion even as some older products face generic competition.

New launches and label expansions in these therapy areas are key to sustaining the revenue trajectory. Novartis continues to allocate a significant portion of its research and development budget to oncology and immunology, targeting late stage assets that can contribute meaningfully to net sales in future years. Investors track the clinical and regulatory pipeline closely because successful approvals can add several billion Swiss francs of potential peak sales, while setbacks may require portfolio rebalancing.

Pipeline, R&D, and margin discipline

Research and development expenditure at Novartis runs into the high single digit billions of Swiss francs per year, reflecting the capital intensive nature of pharmaceutical innovation. This investment is spread across oncology, immunology, cardiovascular, and other segments of the portfolio, with a prioritization of assets that align with the company’s strategic focus on high value medicines. The ratio of R&D spend to net sales provides a lens on how aggressively Novartis is investing relative to its revenue base, and in recent years that ratio has remained consistent with large cap pharma peers.

Margin discipline has been a notable theme in Novartis communication, with the company targeting improvements in core operating margin through productivity measures, portfolio pruning, and optimized manufacturing footprint. Over time, incremental improvements in core margin have contributed to the uplift in core operating income and core EPS, even in years when headline net sales growth was moderate. For equity holders this combination of margin expansion and controlled R&D spending is central to the sustainability of earnings growth.

Novartis also manages a significant generics business through Sandoz, although strategic decisions in recent years have sought to clarify the separation between innovative and generic operations. This focus aims to simplify the corporate structure and allow the innovative medicines segment to be valued on its own merits, driven by high growth assets in oncology and immunology and supported by a sizeable late stage pipeline.

Cosentyx and key product focus

Within the Novartis portfolio, Cosentyx stands out as a flagship immunology product that draws attention in discussions about the company’s medium term growth path. The drug is used to treat psoriasis and other immune mediated conditions and has built a solid franchise with patients and physicians. Revenue from Cosentyx has risen across recent reporting cycles, supporting the broader immunology and dermatology segment and helping to offset pressures in more mature parts of the portfolio.

Other notable products include Kisqali in oncology, which targets hormone receptor positive breast cancer, and various therapies in cardiovascular and respiratory medicine. Each product line contributes a distinct revenue stream, and together they form a diversified base that reduces dependence on any single blockbuster. The spread of products across multiple indications also helps Novartis limit the impact of competition from biosimilars and generics, although lifecycle management remains an ongoing challenge in a sector where patent expirations are a constant feature.

Novartis stock and market positioning

Novartis stock trades in Swiss francs on the SIX Swiss Exchange and reflects the company’s combination of established cash generating assets and emerging growth drivers. The shares are widely held by institutional and retail investors seeking exposure to global healthcare themes, including aging demographics, increased access to therapies, and ongoing innovation in oncology and immunology. In valuation terms, Novartis is often compared with other large cap pharmaceutical groups, with metrics such as price to earnings and enterprise value to EBITDA providing a framework for comparison.

Over successive years, the relationship between core EPS growth and Novartis stock performance has underlined the importance of converting pipeline success into tangible earnings. When core EPS and net sales growth have run ahead of expectations, the stock has tended to be rewarded with higher valuation multiples. Conversely, periods of slower growth or unexpected setbacks in the pipeline have sometimes led to more muted performance. This interplay between fundamentals and share price underscores why detailed attention to revenue, margin, and R&D metrics is central for anyone monitoring Novartis stock.

Key data on Novartis

• Company: Novartis AG
• ISIN: CH0012005267
• Ticker: SIX: NOVN
• Trading venue: SIX Swiss Exchange
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: Swiss Market Index